videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

Ascelia Pharma

Meet and ask questions to CEO Magnus Corfitzen from Ascelia Pharma – Wednesday 23 August at 10.00 CEST. 

It’s been a busy first half-year for Ascelia Pharma and besides the financials CEO Magnus Corfitzen will run through the major highlights and what to expect in the second half of 2023. 

Meet and ask questions to CEO Magnus Corfitzen from Ascelia Pharma &ndash; Wednesday 23 August at 10.00 CEST. It&rsquo;s been a busy first half-year for Ascelia Pharma and besides the financials CEO Magnus Corfitzen will run through the major highlights and what to expect in the second half of 2023. Ascelia Pharma is a Swedish biotech company that focuses on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia Pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detection and visualization of focal liver lesions (Including liver metastases &ndash; and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect &ndash; even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement. Claus Thestrup 11:00 &ndash; 04-07-2023.

Ascelia Pharma – Presentation of Half-Year Report 2023

Recent videos